Coffee; Aspirin; Humans; Life Style; Tremor; Parkinson Disease; Multidisciplinary
Abstract :
[en] Genetic factors, environmental factors, and gene-environment interactions have been found to modify PD risk, age at onset (AAO), and disease progression. The objective of this study was to explore the association of coffee drinking, aspirin intake, and smoking, with motor and non-motor symptoms in a cohort of 35,959 American patients with PD from the Fox Insight Study using generalized linear models. Coffee drinkers had fewer problems swallowing but dosage and duration of coffee intake were not associated with motor or non-motor symptoms. Aspirin intake correlated with more tremor (p = 0.0026), problems getting up (p = 0.0185), light-headedness (p = 0.0043), and problems remembering (p = 1 × 10-5). Smoking was directly associated with symptoms: smokers had more problems with drooling (p = 0.0106), swallowing (p = 0.0002), and freezing (p < 1 × 10-5). Additionally, smokers had more possibly mood-related symptoms: unexplained pains (p < 1 × 10-5), problems remembering (p = 0.0001), and feeling sad (p < 1 × 10-5). Confirmatory and longitudinal studies are warranted to investigate the clinical correlation over time.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Gabbert, Carolin; Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany
König, Inke R; Institute of Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany
Lüth, Theresa; Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany
Kasten, Meike; Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany ; Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany
GRÜNEWALD, Anne ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Molecular and Functional Neurobiology ; University of Lübeck > Institute of Neurogenetics
Klein, Christine; Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany
Trinh, Joanne; Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. joanne.trinh@neuro.uni-luebeck.de
External co-authors :
yes
Language :
English
Title :
Lifestyle factors and clinical severity of Parkinson's disease.
Michael J. Fox Foundation for Parkinson's Research Deutsche Forschungsgemeinschaft Fonds National de la Recherche Luxembourg Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Funding text :
The Fox Insight Study (FI) is funded by The Michael J. Fox Foundation for Parkinson’s Research. We would like to thank the Parkinson’s community for participating in this study to make this research possible.
Gabbert, C. et al. Coffee, smoking and aspirin are associated with age at onset in idiopathic Parkinson’s disease. J. Neurol. 10.1007/s00415-022-11041-x (2022). DOI: 10.1007/s00415-022-11041-x
Marras, C., Canning, C. G. & Goldman, S. M. Environment, lifestyle, and Parkinson’s disease: Implications for prevention in the next decade. Mov. Disord. 34, 801–811. 10.1002/mds.27720 (2019). DOI: 10.1002/mds.27720
Kline, E. M. et al. Genetic and environmental factors in Parkinson’s disease converge on immune function and inflammation. Mov. Disord. 36, 25–36. 10.1002/mds.28411 (2021). DOI: 10.1002/mds.28411
Dunn, A. R., O’Connell, K. M. S. & Kaczorowski, C. C. Gene-by-environment interactions in Alzheimer’s disease and Parkinson’s disease. Neurosci. Biobehav. Rev. 103, 73–80. 10.1016/j.neubiorev.2019.06.018 (2019). DOI: 10.1016/j.neubiorev.2019.06.018
Alves, G., Kurz, M., Lie, S. A. & Larsen, J. P. Cigarette smoking in Parkinson’s disease: Influence on disease progression. Mov. Disord. 19, 1087–1092. 10.1002/mds.20117 (2004). DOI: 10.1002/mds.20117
Cho, B. H., Choi, S. M., Kim, J. T. & Kim, B. C. Association of coffee consumption and non-motor symptoms in drug-naive, early-stage Parkinson’s disease. Parkinson. Relat. Disord. 50, 42–47. 10.1016/j.parkreldis.2018.02.016 (2018). DOI: 10.1016/j.parkreldis.2018.02.016
Cho, B. H., Choi, S. M. & Kim, B. C. Gender-dependent effect of coffee consumption on tremor severity in de novo Parkinson’s disease. BMC Neurol. 19, 194. 10.1186/s12883-019-1427-y (2019). DOI: 10.1186/s12883-019-1427-y
Kandinov, B., Giladi, N. & Korczyn, A. D. The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson’s disease. Parkinson. Relat. Disord. 13, 243–245. 10.1016/j.parkreldis.2006.11.004 (2007). DOI: 10.1016/j.parkreldis.2006.11.004
Moccia, M. et al. Non-motor correlates of smoking habits in de Novo Parkinson’s disease. J. Parkinsons Dis. 5, 913–924. 10.3233/JPD-150639 (2015). DOI: 10.3233/JPD-150639
Villafane, G. et al. High-dose transdermal nicotine in Parkinson’s disease patients: A randomized, open-label, blinded-endpoint evaluation phase 2 study. Eur. J. Neurol. 25, 120–127. 10.1111/ene.13474 (2018). DOI: 10.1111/ene.13474
Postuma, R. B. et al. Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD): A randomized trial. Neurology 89, 1795–1803. 10.1212/WNL.0000000000004568 (2017). DOI: 10.1212/WNL.0000000000004568
Smolensky, L. et al. Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson’s disease. Sci. Data 7, 67. 10.1038/s41597-020-0401-2 (2020). DOI: 10.1038/s41597-020-0401-2
Prediger, R. D. Effects of caffeine in Parkinson’s disease: From neuroprotection to the management of motor and non-motor symptoms. J. Alzheimers Dis. 20(Suppl 1), S205-220. 10.3233/JAD-2010-091459 (2010). DOI: 10.3233/JAD-2010-091459
Hong, C. T., Chan, L. & Bai, C. H. The effect of caffeine on the risk and progression of Parkinson’s disease: A meta-analysis. Nutrients 10.3390/nu12061860 (2020). DOI: 10.3390/nu12061860
van Gelder, B. M. et al. Coffee consumption is inversely associated with cognitive decline in elderly European men: The FINE Study. Eur. J. Clin. Nutr. 61, 226–232. 10.1038/sj.ejcn.1602495 (2007). DOI: 10.1038/sj.ejcn.1602495
Ritchie, K. et al. The neuroprotective effects of caffeine: A prospective population study (the Three City Study). Neurology 69, 536–545. 10.1212/01.wnl.0000266670.35219.0c (2007). DOI: 10.1212/01.wnl.0000266670.35219.0c
Wahner, A. D., Bronstein, J. M., Bordelon, Y. M. & Ritz, B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69, 1836–1842. 10.1212/01.wnl.0000279519.99344.ad (2007). DOI: 10.1212/01.wnl.0000279519.99344.ad
Chen, H. et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann. Neurol. 58, 963–967. 10.1002/ana.20682 (2005). DOI: 10.1002/ana.20682
Ascherio, A. & Schwarzschild, M. A. The epidemiology of Parkinson’s disease: Risk factors and prevention. Lancet Neurol. 15, 1257–1272. 10.1016/S1474-4422(16)30230-7 (2016). DOI: 10.1016/S1474-4422(16)30230-7
Gigante, A. F., Martino, T., Iliceto, G. & Defazio, G. Smoking and age-at-onset of both motor and non-motor symptoms in Parkinson’s disease. Parkinson. Relat. Disord. 45, 94–96. 10.1016/j.parkreldis.2017.09.022 (2017). DOI: 10.1016/j.parkreldis.2017.09.022
Lee, Y. et al. Does smoking impact dopamine neuronal loss in de novo Parkinson disease?. Ann. Neurol. 82, 850–854. 10.1002/ana.25082 (2017). DOI: 10.1002/ana.25082
Nascimento, D., Carmona, J., Mestre, T., Ferreira, J. J. & Guimaraes, I. Drooling rating scales in Parkinson’s disease: A systematic review. Parkinso. Relat. Disord. 91, 173–180. 10.1016/j.parkreldis.2021.09.012 (2021). DOI: 10.1016/j.parkreldis.2021.09.012
Simons, J. A. Swallowing dysfunctions in Parkinson’s disease. Int. Rev. Neurobiol. 134, 1207–1238. 10.1016/bs.irn.2017.05.026 (2017). DOI: 10.1016/bs.irn.2017.05.026
Petrusic, N., Posavac, M., Sabol, I. & Mravak-Stipetic, M. The effect of tobacco smoking on salivation. Acta Stomatol. Croat. 49, 309–315. 10.15644/asc49/4/6 (2015). DOI: 10.15644/asc49/4/6
Plurphanswat, N., Kaestner, R. & Rodu, B. The effect of smoking on mental health. Am. J. Health Behav. 41, 471–483. 10.5993/AJHB.41.4.12 (2017). DOI: 10.5993/AJHB.41.4.12
Snell, M., Harless, D., Shin, S., Cunningham, P. & Barnes, A. A longitudinal assessment of nicotine dependence, mental health, and attempts to quit Smoking: Evidence from waves 1–4 of the Population Assessment of Tobacco and Health (PATH) study. Addict. Behav. 115, 106787. 10.1016/j.addbeh.2020.106787 (2021). DOI: 10.1016/j.addbeh.2020.106787
Weinberger, A. H. et al. Depression and cigarette smoking behavior: A critical review of population-based studies. Am. J. Drug Alcohol Abuse 43, 416–431. 10.3109/00952990.2016.1171327 (2017). DOI: 10.3109/00952990.2016.1171327
Tomita, A. & Manuel, J. I. Evidence on the Association Between Cigarette Smoking and Incident Depression from the South African National Income Dynamics Study 2008–2015: Mental health implications for a resource-limited setting. Nicotine Tob. Res. 22, 118–123. 10.1093/ntr/nty163 (2020). DOI: 10.1093/ntr/nty163
Grover, S. et al. Genome-wide association and meta-analysis of age at onset in Parkinson disease: Evidence from the COURAGE-PD consortium. Neurology 99, e698–e710. 10.1212/WNL.0000000000200699 (2022). DOI: 10.1212/WNL.0000000000200699
Kolicheski, A. et al. Early-onset Parkinson’s disease: Creating the right environment for a genetic disorder. J. Parkinsons Dis. 12, 2353–2367. 10.3233/JPD-223380 (2022). DOI: 10.3233/JPD-223380
Chahine, L. M. et al. Comparison of an online-only Parkinson’s disease research cohort to cohorts assessed in person. J. Parkinsons Dis. 10, 677–691. 10.3233/JPD-191808 (2020). DOI: 10.3233/JPD-191808
Dobkin, R. D. et al. Innovative recruitment strategies to increase diversity of participation in Parkinson’s disease research: The fox insight cohort experience. J. Parkinsons Dis. 10, 665–675. 10.3233/JPD-191901 (2020). DOI: 10.3233/JPD-191901
Dewey, R. B. Jr. Management of motor complications in Parkinson’s disease. Neurology 62, S3-7. 10.1212/wnl.62.6_suppl_4.s3 (2004). DOI: 10.1212/wnl.62.6_suppl_4.s3
Chou, K. L. et al. The spectrum of “off” in Parkinson’s disease: What have we learned over 40 years?. Parkinson. Relat. Disord. 51, 9–16. 10.1016/j.parkreldis.2018.02.001 (2018). DOI: 10.1016/j.parkreldis.2018.02.001
